Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups
Open Access
- 1 February 2014
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (2), 833-838
- https://doi.org/10.1128/aac.01896-13
Abstract
Escherichia coli (328 isolates), Klebsiella pneumoniae (296), Klebsiella oxytoca (44), and Proteus mirabilis (33) isolates collected during 2012 from the nine U.S. census regions and displaying extended-spectrum-β-lactamase (ESBL) phenotypes were evaluated for the presence of β-lactamase genes, and antimicrobial susceptibility profiles were analyzed. The highest ESBL rates were noted for K. pneumoniae (16.0%, versus 4.8 to 11.9% for the other species) and in the Mid-Atlantic and West South Central census regions. CTX-M group 1 (including CTX-M-15) was detected in 303 strains and was widespread throughout the United States but was more prevalent in the West South Central, Mid-Atlantic, and East North Central regions. KPC producers (118 strains [112 K. pneumoniae strains]) were detected in all regions and were most frequent in the Mid-Atlantic region (58 strains). Thirteen KPC producers also carried bla CTX-M . SHV genes encoding ESBL activity were detected among 176 isolates. Other β-lactamase genes observed were CTX-M group 9 (72 isolates), FOX (10), TEM ESBL (9), DHA (7), CTX-M group 2 (3), NDM-1 (2 [Colorado]), and CTX-M groups 8 and 25 (1). Additionally, 62.9% of isolates carried ≥2 β-lactamase genes. KPC producers were highly resistant to multiple agents, but ceftazidime-avibactam (MIC 50/90 , 0.5/2 μg/ml) and tigecycline (MIC 50/90 , 0.5/1 μg/ml) were the most active agents tested. Overall, meropenem (MIC 50 , ≤0.06 μg/ml), ceftazidime-avibactam (MIC 50 , 0.12 to 0.5 μg/ml), and tigecycline (MIC 50 , 0.12 to 2 μg/ml) were the most active antimicrobials when tested against this collection. NDM-1 producers were resistant to all β-lactams tested. The diversity and increasing prevalence of β-lactamase-producing Enterobacteriaceae have been documented, and ceftazidime-avibactam was very active against the vast majority of β-lactamase-producing strains isolated from U.S. hospitals.Keywords
This publication has 17 references indexed in Scilit:
- Rapid Expansion of KPC-2-Producing Klebsiella pneumoniae Isolates in Two Texas Hospitals due to Clonal Spread of ST258 and ST307 LineagesMicrobial Drug Resistance, 2013
- Colistin-Resistant, Klebsiella pneumoniae Carbapenemase (KPC)-Producing Klebsiella pneumoniae Belonging to the International Epidemic Clone ST258Clinical Infectious Diseases, 2011
- Carbapenem-Resistant Enterobacteriaceae: Epidemiology and PreventionClinical Infectious Diseases, 2011
- Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007–09)Journal of Antimicrobial Chemotherapy, 2011
- Comment on: role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-β-lactamases.Journal of Antimicrobial Chemotherapy, 2010
- Escherichia coliSequence Type ST131 as the Major Cause of Serious Multidrug‐ResistantE. coliInfections in the United StatesClinical Infectious Diseases, 2010
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemasesJournal of Antimicrobial Chemotherapy, 2009
- Rapid Emergence ofblaCTX-MAmong Enterobacteriaceae in U.S. Medical Centers: Molecular Evaluation from the MYSTIC Program (2007)Microbial Drug Resistance, 2008
- Extended-spectrum β-lactamases in North America, 1987–2006Clinical Microbiology & Infection, 2008
- Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain ofKlebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2001